跳至主要内容
临床试验/NCT01295879
NCT01295879已完成4 期

Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria

New York Presbyterian Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Change in 24 Hour Urine Calcium

研究概览

简要总结

Vitamin D plays a critical role in maintaining bone health, as well as preventing cardiovascular disease, cancer, and various autoimmune diseases, such as diabetes. Vitamin D deficiency is very common in the United States and worldwide, and is now being increasingly recognized and treated. One group in which vitamin D deficiency may be particularly important is patients who have had kidney stones. These patients frequently have elevated levels of calcium in their urine, which is a common and important risk factor for calcium containing kidney stones. Because vitamin D increases absorption of calcium into the blood by the intestines, physicians may be reluctant to prescribe vitamin D therapy to patients with vitamin D deficiency if they also have kidney stones and high amounts of calcium in the urine. They are concerned about the possible risk of increasing the amount of calcium in the urine (and thereby increasing the risk of calcium stones occurring again). However, studies in patients without kidney stones, as well as studies in patients with high calcium levels in the urine, have demonstrated that giving vitamin D is effective and safe and does not increase calcium in the urine. Therefore, the investigators will study the effects of giving vitamin D on the amount of calcium in the urine in patients with a history of kidney stones and elevated calcium in the urine. The investigators will evaluate the safety of giving vitamin D to this particular group of patients.

详细描述

The investigators plan to conduct a clinic-based interventional study of 30 patients followed at outpatient urology clinics associated with New York Presbyterian Hospital (NYPH). The intervention is supplementation with oral ergocalciferol 50,000 IU per week for 8 weeks, and each participant will serve as his/her own control. The formulation, dose, and duration of vitamin D therapy is reflective of that which is given in routine clinical practice to patients with vitamin D deficiency. The outcome is the change in urinary calcium excretion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • History of nephrolithiasis as per medical record
  • Urinary calcium excretion between 150 and 400 mg/day (measured within 3 months of study enrollment)
  • 25(OH)D deficiency or insufficiency (defined as a serum level < 30 ng/ml) within 3 months of enrollment

排除标准

  • Pregnant women, since the optimal dose of vitamin D supplementation in this population has not been rigorously studied.
  • Known uric acid, cystine, or struvite stone disease (because our intervention is predominantly aimed at patients with calcium stone disease). An exception to this is patients who have passed both uric acid and calcium stones, or patients who have passed stones of mixed composition (uric acid and calcium).
  • Hypercalcemia (serum calcium > 10.4 mg/dL) at baseline
  • Acute stone event or gross hematuria (blood in the urine) within the past 2 months
  • Recent stone intervention within the past 1 month
  • Suspected or known secondary causes of hypercalciuria, such as primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or malignancy (except nonmelanoma skin cancer)
  • Addition or dose change of medicines potentially affecting urinary calcium since the baseline 24hour urine collection (including diuretics, magnesium supplements, potassium supplements, potassium citrate, and vitamin D supplementation)

研究组 & 干预措施

Ergocalciferol

Experimental

Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks

干预措施: Ergocalciferol (Drug)

结局指标

主要结局

Change in 24 Hour Urine Calcium

时间窗: 8 weeks

Elevated values of urine calcium are a risk factor for recurrence of calcium kidney stones

次要结局

  • Change in 24 Hour Urine Supersaturation of Calcium Oxalate(8 weeks)
  • Recurrence of Kidney Stones(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David E. Leaf

Nephrology Fellow

New York Presbyterian Hospital

研究点 (1)

Loading locations...

相似试验